A dvancement in the diagnosis and treatment of pediatric acute lymphoblastic leukemia (ALL) is one of the greatest successes of modern medicine. Over the past 50 years, there has been a rapid increase in overall survival for pediatric ALL (Figure 1) . Several factors have led to these remarkable improvements. First is the development of riskadapted therapy based on both clinical and biological presenting features, as well as early response to treatment. 2 Second, the effectiveness of molecularly targeted agents for specific genetic abnormalities has boosted outcomes for some high-risk groups. 2 Third, international collaboration among clinical trial networks has led to standardization of definitions and reporting of results, allowing comparison of data across multiple national study groups to identify optimal treatments (Table; available at www.jpeds.com). [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Today, the long-term survival rate for pediatric ALL is approaching 90% in many high-income countries, the highest of any type of leukemia in either children or adults. 19 These remarkable achievements notwithstanding, a number of challenges in ALL pathology and treatment remain to be addressed. Relapse still occurs in 10%-15% of patients, and death due to relapsed ALL remains one of the leading causes of cancer mortality in children. Conventional cytotoxic chemotherapy continues to be associated with both short-and long-term toxic effects and is unlikely to be modified substantially in the near future. Thus, it will be important to take advantage of emerging molecular and immunologic insights to improve risk stratification and devise targeted therapies to avoid overtreatment or undertreatment.
In this review, we discuss advances in the diagnosis and treatment of pediatric ALL that are reshaping the landscape of this disease. In the future, all patients may undergo genetic sequencing of both cancer and germline genomes to increase the precision of risk stratification and hence the specificity of treatment. Patients with high-risk genetic subtypes or poor response to treatment, as measured by minimal residual disease (MRD), may benefit from molecularly targeted therapy or immunotherapy. With advances in identifying molecular lesions that are amenable to targeted therapy and in developing riskadapted therapy for ALL, we believe that precision medicine will drive ALL treatment in the future.
Evaluation and Risk Stratification
Risk stratification of patients with pediatric ALL is used to determine the optimal type, intensity, and duration of treatment. Here we discuss risk stratification based on the following factors: (1) clinical presenting features, (2) leukemia genetic subtype, (3) germline cancer predisposition, and (4) initial response to treatment as measured by MRD (Figure 2 ).
Clinical Presenting Features
Age and white blood cell (WBC) count at presentation are used to risk-stratify patients with pediatric ALL, according to National Cancer Institute consensus criteria.
20 High-risk features include age <1 year or >10 years and WBC count >50 000 cells/ mm 3 . Extramedullary involvement at sanctuary sites, such as the central nervous system and testes, and prolonged pretreatment with corticosteroids are also considered high-risk features.
In addition to presenting features, genetic evaluation has important prognostic and therapeutic implications. Increasingly, genome sequencing technologies are being used to diagnose and guide therapy for pediatric ALL.
Next-Generation Sequencing
Next-generation sequencing (NGS) is the latest genomic sequencing technology that enables high-throughput, massively parallel DNA sequencing. 21 In pediatric ALL, NGS is being increasingly used to comprehensively define the somatic genetic alterations and the role of inherited genetic variants in leukemogenesis, to monitor drug response and treatment toxicity, and to enhance the sensitivity of MRD detection compared with current methods.
22-30 Indeed, NGS of both host and cancer genomes is required to develop truly personalized riskadapted therapy (Figure 2 ). (Figure 2 ). High-Risk Subtypes. Patients with high-risk disease should be identified early in therapy because they benefit from intensified induction and consolidative treatment. Among patients with B-ALL, a high-risk group harbor the Philadelphia chromosome (Ph), the product of a t(9;22) translocation that results in BCR-ABL1 fusion, which can be treated with ABL1 tyrosine kinase inhibitors (TKIs). Ph + ALL generally occurs in older children and has a poor prognosis overall.
32
Ph-like ALL is another high-risk subtype of B-ALL characterized by a gene expression profile and a high frequency of IKZF1 alterations similar to those in Ph + ALL but lacking BCR-ABL1 fusion. 29, 33 Among this clinically and biologically heterogeneous group, a wide range of genetic alterations in Phlike ALL results in dysregulation of several cytokine receptors and kinase signaling pathways.
27,33 Alteration in IKZF1 is an independent risk factor associated with poor prognosis. [33] [34] [35] [36] [37] Additional treatment strategies are needed for this high-risk group, particularly for a subset of patients termed IKZF plus with certain co-occurring mutations that confer the worst prognosis among patients with Ph-like ALL. 38 Notably, a subset of these patients with IKZF1 plus with rapid early response had excellent outcomes, emphasizing the utility of MRD assessment in assigning risk of relapse, even in patients with high-risk ALL.
Older children are also more likely to harbor rearrangements involving the MEF2D gene, a recently identified fusion partner that carries a high risk of relapse. 39, 40 For some high-risk groups, such as those with intrachromosomal amplification of chromosome 21 (iAMP21), intensification of Volume 203 • December 2018 conventional chemotherapy has led to a reduced risk of relapse. [41] [42] [43] [44] Treatment outcomes for infant ALL remain poor. Among infants with B-ALL, chromosomal translocations involving the mixed lineage leukemia (MLL/KMT2A) gene are common and are associated with high rates of induction failure and relapse. 45 Hypodiploid ALL with fewer than 44 chromosomes is another high-risk subtype of ALL.
23, 46 Of interest, lowhypodiploid ALL with 32-39 chromosomes is characterized by a high frequency of genetic alterations of TP53 that are often inherited. 46 A recent study suggested that response-adapted treatment can improve outcomes in patients with lowhypodiploid ALL who attain MRD-negative status after remission induction, because these patients have a high cure rate with intensive chemotherapy. 46 Among patients with T-ALL, those with early T-cell precursor ALL have an especially poor response to induction therapy. [47] [48] [49] Patients in this high-risk group typically lack specific chromosomal rearrangements, but they share a distinct gene expression profile and immunophenotype of a subset of thymocytes that retain stem cell-like features. 47 Recent studies suggest that patients with early T-cell precursor ALL may benefit from intensive consolidative treatment with cyclophosphamide, mercaptopurine, and cytarabine and may not require hematopoietic stem cell transplantation (HSCT).
50,51
Intermediate-Risk Subtypes. Patients with intermediaterisk disease require intensive chemotherapy to prevent relapse and are not candidates for treatment reduction. Approximately one-half of all cases of B-ALL would be classified as intermediate risk, including those recently found to have translocations involving the ZNF384 gene. 39, 52 Patients with T-ALL with abnormalities in the tumor-suppressor gene PTEN have intermediate outcomes, although the prognosis depends on the mechanism of PTEN inactivation. [53] [54] [55] MLL rearrangements also have been observed in T-ALL, but these patients have better outcomes than those with B-ALL and MLL rearrangements. 56, 57 Low-Risk Subtypes. Patients with low-risk subtypes of pediatric ALL may be considered excellent candidates for Factors influencing risk stratification and outcome for patients with ALL. Clinical presenting features, leukemia cell genetics (cancer genome), host germline genome, and minimal residual disease should be considered when determining riskadapted therapy. Advances in whole-genome sequencing of both host (germline) and cancer (leukemia) genomes has deepened our understanding of genetic factors that determine risk (high, intermediate, and low risk) and influence on treatment response and toxicity of cytotoxic chemotherapy agents.
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Volume 203 treatment reduction to decrease the toxicity associated with intensive chemotherapy. However, such reduction should be applied judiciously to "rapid early responders" with negative MRD and favorable leukemia genetic subtype so that the overall cure rate is not compromised. In a recent study, "standardrisk" patients (defined by favorable age 1-10 years and WBC count <50 000 cells/mm 3 ) with unfavorable leukemia genetics who were rapid early responders had worse outcomes when delayed intensification treatment was reduced. 58 We contend that only patients with B-ALL with low-risk genetic features, such as ETV6-RUNX1 fusion (previously known as TEL-AML1), trisomies 4 and 10, or hyperdiploid ALL, and rapid early response to treatment after 1-2 weeks of 3-drug remission induction are good candidates for treatment reduction. 58 In patients with T-ALL, those with NOTCH/FBXW7 mutations have favorable outcomes.
59-61
Detecting Minimal Residual Disease Risk-adapted therapy guided by MRD level measured during remission induction and consolidation treatment has contributed greatly to the improved outcome in pediatric ALL.
14,62
Because it accounts for leukemic cell genetics, host pharmacogenetics, leukemia cell environment, and treatment efficacy, the MRD level has become an important prognostic factor in ALL. 63 High levels of MRD at the end of remission induction or persistent MRD after consolidative treatment is an indication for intensification of treatment or even HSCT.
Traditionally, MRD has been measured with multicolor flow cytometry or quantitative PCR (qPCR). Recent studies based on NGS showed enhanced sensitivity and specificity compared with standard methods of MRD detection in both Band T-ALL. 64, 65 These results suggest that NGS may detect as few as 1 leukemic blast out of 1 million normal cells, corresponding to a 10-fold greater sensitivity than qPCR and a 100-fold greater sensitivity than flow cytometry. 66, 67 In this regard, negative MRD findings by NGS can identify a subgroup of rapid early responders who appear to be at even lower risk of relapse with chemotherapy or after HSCT compared with those with negative MRD defined by flow cytometry or qPCR (with limits of <1 leukemic cell among 10 000 normal cells). [68] [69] [70] Predicting Treatment Failure and Toxicity More recently, NGS has revealed genetic variations in the host and cancer genome that may predict the risk of treatment failure and toxicity associated with chemotherapy (Figure 2) . For example, patients with B-ALL harboring activating mutations in the CREB-binding protein (CREBBP) gene have high rates of relapse associated with resistance to glucocorticoids, 71 and those with activating mutations in NT5C2 or loss-offunction mutations in PRPS1 are resistant to thiopurines, such as mercaptopurine. 72, 73 Understanding how these mutations confer drug resistance may inform the design of optimal frontline or salvage therapy.
Genome-wide analyses have also uncovered genetic variations in the host germline genome that are associated with particular adverse outcomes of chemotherapy (Figure 2) . For example, both thiopurine methyltransferase (TPMT) and nudix hydrolase 15 (NUDT15) genetic polymorphisms have been associated with intolerance to thiopurine treatment; that is, patients with homozygous polymorphisms are at increased risk of life-threatening myelosuppression when exposed to conventional doses of thiopurines, such as mercaptopurine. 74, 75 Similarly, patients with polymorphisms in the promoter region of the centrosomal protein 72 (CEP72) gene, which encodes a protein involved in microtubule assembly, have an increased risk of severe peripheral neuropathy when treated with vincristine. 76 More recent discoveries include genetic polymorphisms associated with increased risk of steroid-induced osteonecrosis and methotrexate-related mucositis. [77] [78] [79] As genome-wide analyses such as NGS become widely available, future treatment plans could use genomic technology to prospectively identify patients at high risk of treatment intolerance to dose-adjust chemotherapy and minimize morbidity.
Cancer Predisposition Genes in Pediatric ALL
Epidemiologic studies have demonstrated different frequencies of pediatric ALL among various ethnic groups. Children of Hispanic or Native American ancestry have the highest incidence of ALL, followed by those of European descent, and finally by those of African descent. 80 Population-based genomewide association studies have revealed ethnicity-specific polymorphisms that may account for these patterns; for example, the highest frequencies of polymorphisms in the ARID5B, BMI1-PIP4K2A, and GATA3 genes were found among Hispanics. [81] [82] [83] These germline risk alleles also can influence treatment outcomes, as illustrated by GATA3 variants associated with Ph-like ALL and poor outcome. 83 Recent studies have revealed germline mutations in cancer predisposition genes associated with a high risk of developing ALL, such as TP53, PAX5, ETV6, and IKZF1, in up to 5% of pediatric patients with ALL. [84] [85] [86] [87] [88] [89] Such results have implications not only for the patients, but also for their families, because close relatives may benefit from genetic testing, counseling, and surveillance. Notably, patients with TP53 germline variations also have an increased risk of relapse and development of second cancers. 90 
Personalized Treatment
Pediatric ALL is a highly disseminated and heterogeneous disease, warranting the current focus on personalized treatment. At most centers, therapy for this disease is tailored to the patient's specific genetic subtype, extent of disease, and drug sensitivity as assessed by MRD after remission induction or consolidative treatment. Patients with high-risk genetic subtypes, disseminated disease involving sanctuary sites such as the central nervous system or testes, or a positive MRD finding after remission induction typically require more intensive chemotherapy to prevent recurrence. Although uniform treatment of large groups of patients has become a relic of the past, there remains a need for standardized, protocol-directed therapy, which currently proceeds in 3 phases: induction, consolidative therapy, and maintenance.
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Conventional Cytotoxic Chemotherapy
Initial treatment with induction chemotherapy eliminates 99.99% or more of leukemia cells. This phase of treatment most often begins with 4 weeks of vincristine, a corticosteroid (prednisone or dexamethasone), and asparaginase, with the addition of an anthracycline (doxorubicin or daunorubicin) for patients with higher-risk leukemia. 91 The next phase of treatment aims to further reduce submicroscopic leukemia, and thus is termed consolidative therapy. The duration, intensity, choice of agent, and number of treatment courses used during this phase varies according to risk group and protocol, but consolidative therapy typically involves high-dose methotrexate, mercaptopurine, asparaginase, dexamethasone, and vincristine, with or without an anthracycline. For high-risk patients, cytarabine and cyclophosphamide may be added to postinduction consolidative therapy; however, these agents might not be necessary for low-or standard-risk patients, especially in light of their potential effects on future fertility. 92 The final phase of treatment, the so-called maintenance or continuation component, aims to eradicate any remaining leukemic or preleukemic cells and consists of antimetabolites (daily mercaptopurine and weekly methotrexate) with or without pulses of a corticosteroid plus vincristine. Dexamethasone improves survival in patients aged <10 years; however, prednisone is used in lieu of dexamethasone for patients aged >10 years in some protocols out of concern for increased risk of osteonecrosis associated with dexamethasone treatment in this age group. 4 Although 1 study found that two-thirds of patients (including 16 of the 18 patients with ETV6-RUNX1 B-ALL) could be cured with 1 year of maintenance treatment, 93 this phase typically lasts for 2-2.5 years in virtually all contemporary protocols, given the lack of reliable markers to identify patients who may be cured with abbreviated treatment.
It is quite possible that cytotoxic chemotherapy may someday be replaced by shorter treatments with targeted agents (Figure 3) , but until the genes and pathways essential for leukemia cell survival can be targeted with certainty, the need for distinct phases of chemotherapy will likely persist.
Targeted Therapy
NGS has revolutionized the treatment of pediatric ALL by revealing genetic alterations that are amenable to targeted therapy. Indeed, initiatives such as the St Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project (PCGP) and the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) Project, have 
THE JOURNAL OF PEDIATRICS • www.jpeds.com
Volume 203 uncovered a number of novel genetic alterations in pediatric ALL. 94, 95 Thus far, trials of promising targeted therapies have significantly improved outcomes for some high-risk groups, such as patients with Ph + ALL and subsets of those with Phlike ALL with ABL class fusion transcripts. Novel immunotherapeutic approaches, including chimeric antigen receptor (CAR)-based cellular therapies, also have cured a substantial proportion of patients with highly refractory leukemia, some of whom had relapsed after HSCT (Figure 3) . A representative selection of immunologic-and genetic-based treatment strategies are described below.
ABL1 Tyrosine Kinase Inhibitors in Ph
+ ALL The first successful use of precision medicine in childhood ALL began with the discovery that Ph + B-ALL with the BCR-ABL1 fusion was sensitive to ABL1 TKIs. [96] [97] [98] [99] Once associated with dismal prognosis despite HSCT, 32 the outcome for Ph + ALL has significantly improved since the ABL1 TKI imatinib was incorporated into an intensive chemotherapy regimen. [96] [97] [98] [99] Dasatinib, a second-generation ABL1 TKI targeting multiple kinases, has comparable safety and efficacy to imatinib, and reduced the need for HSCT in a recently completed phase II clinical trial (NCT01460160). 100, 101 Ponatinib, a third-generation ABL1 TKI, is more effective than earlier generations of ABL1 TKIs in adults; however, due to the associated toxicities, 102 it should be used and dosed judiciously in children.
ABL1 TKIs and Janus Kinase Inhibitors in
Ph-Like ALL Ph-like ALL is characterized by a wide range of genetic alterations that dysregulate several cytokine receptor and kinase signaling pathways, including CRLF2 rearrangement in onehalf of cases and translocation of nonreceptor tyrosine kinases (predominantly ABL class and Janus kinase [JAK]). 103 Patients with ABL class fusions (including ABL1, ABL2, CSF1R, PDGFRB, and PDGFRA) respond clinically to ABL1 TKIs, whereas in preclinical models mutations activating the JAK-STAT pathway have been amenable to treatment with JAK inhibitors (eg, ruxolitinib). 27 Ongoing studies are testing whether incorporating a TKI targeting kinase alterations into intensive chemotherapy regimens will improve outcomes in patients with Ph-like ALL (NCT02723994 and NCT03117751). 104, 105 BCL2 Inhibitors. Preclinical studies have shown that a new class of drugs targeting the transcription factor BCL2 holds promise for MLL (KMT2A)-rearranged ALL and Ph + ALL.
106,107
The BCL2 inhibitors venetoclax and navitoclax work by forcing leukemic cells to undergo apoptotic programmed cell death.
106
A phase II clinical trial of venetoclax in adults with relapsed or refractory chronic lymphocytic leukemia showed a response rate of approximately 80%. 108 Pediatric clinical trials of venetoclax are currently underway for children with relapsed or refractory ALL (NCT03236857).
109
FMS-Like Tyrosine Kinase 3 Inhibitors. MLL-rearranged ALL displays constitutive activation of FMS-like tyrosine kinase (FLT3), and a subset harbor genetic alterations in this gene. 110, 111 In MLL-rearranged ALL, FLT3 alterations are associated with a poor prognosis. 112, 113 A phase III trial of the FLT3 inhibitor lestaurtinib (CEP-701) in combination with cytotoxic chemotherapy showed no benefit over chemotherapy alone (NCT00557193). 114, 115 Phase I/II trials conducted for the FLT3 inhibitors sorafenib, 116 midostaurin, 117 and quizartinib (AC220) 118 have demonstrated safety and tolerability, but further trials are needed to determine efficacy.
Nucleoside Analogs. Nucleoside analogs are currently in clinical trials for B-ALL and T-ALL. A phase II trial of the purine analog clofarabine in combination with cyclophosphamide and etoposide for relapsed B-ALL found an overall response rate of 44%. 119 For newly diagnosed T-ALL, a recent phase III trial of the purine analog nelarabine in combination with intensive chemotherapy demonstrated improved disease-free survival without excessive toxicity. 120 In the future, incorporating nelarabine into upfront therapy for T-ALL may become the standard of care.
Immunotherapy
Chimeric Antigen Receptor-T Cells. For patients with relapsed B-ALL, the most significant advance in the past decade has been the development of immunotherapies using CAR-T cells. These genetically engineered autologous T cells are able to recognize and kill leukemic B cells bearing their target antigen. 121 The most commonly used CAR consists of an extracellular immunoglobulin domain that recognizes CD19 and an intracellular T-cell signaling domain that activates T cells to kill CD19
+ leukemia cells (Figure 3) . Because normal B cells also express CD19, these patients also develop B-cell aplasia and require monthly intravenous immunoglobulin replacement therapy. 122 Unlike chemotherapy, in which the therapeutic window is limited by the pharmacokinetics of drug clearance, CAR-T cells can persist for months or years in vivo, depending on the costimulatory molecule used, to provide longterm immune surveillance against leukemia cells.
123
The first pediatric phase I trial of CD19-directed CAR-T cell therapy (CTL019) demonstrated complete remissions in 93% of patients with multiply relapsed B-ALL, two-thirds of whom had undergone previous HSCT. 124, 125 Remarkably, relapse-free survival rates were 76% at 6 months and 55% at 12 months. 124, 125 In patients who relapsed, the leukemic cells evaded immunotherapy by 2 mechanisms: CAR-T cells did not persist, and the leukemia reemerged as a CD19-negative clone. 124, 126 To circumvent the problem of CD19 escape, CAR-T cells targeting another B-ALL-associated antigen (CD22) have been developed. 127 In addition, tandem CARs recognizing both CD19 and CD22 on leukemic B cells is another strategy currently in preclinical development. 128 Phase II trials of CAR-T cell therapy are currently underway.
In 2017, the Food and Drug Administration designated CD19-directed CAR-T cells a "breakthrough therapy" and approved CTL019 for relapsed pediatric and adult B-ALL. Given the therapeutic results reported thus far, it seems reasonable to predict that CAR-T cell-based immunotherapy eventually December 2018
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will be incorporated into frontline treatments for high-risk pediatric ALL, and possibly could replace HSCT for patients with relapsed or refractory ALL.
Bispecific T-Cell Engagers. Currently, autologous CAR-T cell therapy has several limitations, including a lengthy and costly manufacturing process that sometimes results in failure to produce these genetically engineered cells. Therefore, some patients with rapidly progressive leukemia are unable to receive CAR-T cell therapy. 129 An alternative immunotherapeutic class of drugs, bispecific T-cell engagers, can eliminate these obstacles. These bispecific T-cell engagers contain 2 domains: a CD19 or CD20 recognition domain that binds to leukemic B cells, and a T-cell receptor recognition domain that binds and activates T cells to kill leukemic B cells. 129, 130 These bispecific antibodies can be used in patients for whom no T cells are available, and are available immediately as "off the shelf " products.
The most potent drug of this class-blinatumomab-had a response rate of 39% in a phase I/II trial of patients with relapsed or refractory B-ALL. 130 Another study demonstrated durable remissions in pediatric patients who had undergone HSCT. 131 However, in patients with overt or multiple relapses, blinatumomab by itself did not induce durable remissions, and instead was used as a bridge to HSCT. 130 Ongoing clinical trials are testing whether blinatumomab in combination with intensive chemotherapy can improve outcomes in patients with newly diagnosed B-ALL and persistent MRD after remission and consolidative therapy, in the absence of HSCT.
Conclusions
Future progress in pediatric ALL research will be driven not only by advances in science and technology, but also by greater international collaboration among investigators to standardize risk group classification, definition of treatment response, and toxicity criteria. Innovations in genomic sequencing can be expected to aid in diagnosis, identify targetable lesions, and guide risk stratification to optimize therapy, and novel therapies likely will become available for various disease subtypes. At the same time, efforts to optimize immunotherapy for relapsed and refractory disease should yield clear breakthroughs in this challenging research area. Whether immunotherapy and molecular targeting strategies will ultimately replace cytotoxic chemotherapy for ALL remains unclear, although recent observations of durable complete remissions among patients responding to targeted therapies after failing chemotherapy or HSCT suggest a major impact of this approach in the future. Finally, as more attention is directed toward smaller subsets of patients with drug-resistant leukemia, the importance of collaborative international research will grow considerably so that therapeutic gains in high-income countries can be translated to patients in middle-or lowincome countries. 132 Finally, increasing our understanding of the biology of ALL and factors that predispose patients to leukemia may lead to preventive measures to decrease the risk of ALL in the future. ■ 
